TY - JOUR
T1 - The 'magic' of L-dopa
T2 - Why is it the gold standard Parkinson's disease therapy?
AU - Mercuri, Nicola Biagio
AU - Bernardi, Giorgio
PY - 2005/7
Y1 - 2005/7
N2 - The chronic treatment of Parkinson's disease with l-dopa is often associated with fluctuations of motor response and dyskinesias. Therefore, to overcome the adverse effects of the long-term use of l-dopa, directly acting dopamine receptor agonists have been introduced. However, l-dopa remains the most effective treatment of the slowness of movement, increased muscle tone, and tremor that are typical of Parkinson's disease. Why is this so? In this article, we discuss evidence that suggests that dopamine produced from l-dopa has a larger number of actions compared with dopamine receptor agonists. In addition to stimulating D1- and D2-like dopamine receptors, dopamine might also activate adrenoceptors, novel dopamine sites, the dopamine transporter and trace amine receptors, all of which might contribute to the superior effect of l-dopa in Parkinson's disease.
AB - The chronic treatment of Parkinson's disease with l-dopa is often associated with fluctuations of motor response and dyskinesias. Therefore, to overcome the adverse effects of the long-term use of l-dopa, directly acting dopamine receptor agonists have been introduced. However, l-dopa remains the most effective treatment of the slowness of movement, increased muscle tone, and tremor that are typical of Parkinson's disease. Why is this so? In this article, we discuss evidence that suggests that dopamine produced from l-dopa has a larger number of actions compared with dopamine receptor agonists. In addition to stimulating D1- and D2-like dopamine receptors, dopamine might also activate adrenoceptors, novel dopamine sites, the dopamine transporter and trace amine receptors, all of which might contribute to the superior effect of l-dopa in Parkinson's disease.
UR - http://www.scopus.com/inward/record.url?scp=20544476874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20544476874&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2005.05.002
DO - 10.1016/j.tips.2005.05.002
M3 - Article
C2 - 15936832
AN - SCOPUS:20544476874
VL - 26
SP - 341
EP - 344
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
SN - 0165-6147
IS - 7
ER -